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Treatment failure in hepatitis C: Mechanisms of non-responseq
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Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, WRN 1007, 55 Fruit Street, Boston, MA 02114, USAHepatitis C virus (HCV) has evolved remarkable mechanisms that favor viral persistence by interfering with host innate
and adaptive immune responses. These same mechanisms are likely to contribute to resistance to exogenously administered
interferon used for HCV treatment. We review the host innate and adaptive immune responses in the context of HCV
infection as well as the strategies by which these responses are subverted by the virus. In addition, the contribution of host
factors, such as race and insulin resistance, to interferon non-responsiveness is discussed. Our progress in understanding
the molecular underpinnings of interferon treatment failure in HCV infection has resulted in several promising and novel
treatment strategies for HCV treatment non-responders.
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Hepatitis C virus (HCV) infection results in chronic
infection in approximately 80% of exposed individuals.
The high frequency of HCV chronicity as an outcome
of exposure is striking, as HCV is an RNA virus with
no DNA intermediate and no ability to integrate into
the host genome in a latent form. It is therefore clear
that HCV has evolved remarkable mechanisms to assure
its persistence in the infected host, despite innate and
adaptive host antiviral responses.
Type I interferon signaling is pivotal to the innate
immune response, and exogenously administered inter-
feron treatment regimens are the current standard of0168-8278/$34.00  2008 European Association for the Study of the Liver.
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onse; SVR, sustained virologic response.care for the treatment of chronic HCV infection. How-
ever, the combination of pegylated interferon and riba-
virin is eﬀective in only about 50% of all patients with
HCV infection. Given the critical role for type I interfer-
ons in innate immunity against HCV, it is likely that the
mechanisms that favor viral chronicity also contribute
to non-response to interferon-based therapy.
1.1. Type I interferon and the innate immune response to
HCV infection
Innate immunity to the hepatitis C virus is triggered
by activation of cellular sensors that recognize the pres-
ence of pathogen-associated molecular patterns, or
PAMPs. The two key cellular sensors in the context of
HCV infection are Toll-like receptor 3 (TLR3), which
senses double-stranded RNA (dsRNA) within endo-
somes, and the RNA helicase RIG-I, which senses intra-
cellular double-stranded RNA or single-stranded viral
RNA with a 50-triphosphate (Fig. 1). Signaling initiated
by TLR3 and RIG-I is transmitted through the adaptor
proteins TRIF and Cardif (also known as IPS-1, VISA,
or MAVS), respectively, to converge on the transcrip-
tion factors IRF3 and NF-jB. IRF3 is phosphorylated
by IKKe and TBK1, resulting in its dimerization and
nuclear translocation.Published by Elsevier B.V. All rights reserved.
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Fig. 2. Classiﬁcation of interferon response and non-response. This plot
depicts three diﬀerent possible responses of the HCV serum RNA titer to
interferon-based therapy in a hypothetical patient with genotype 1 HCV
infection. A null response or non-response (black squares) is convention-
ally deﬁned by a failure of the HCV RNA titer to fall by at least 2 log10
by 12 weeks of treatment. The most commonly used deﬁnition of a slow
response (grey triangles) is a fall of the HCV RNA by at least 2 log10 by
12 weeks of treatment but detectable viremia that then clears by week 24.
A rapid response (white circles) indicates that the HCV RNA is
undetectable at 4 weeks of treatment by the most sensitive available test
(typically quantitative RT-PCR based methods) with a typical threshold
of 10 IU/mL. Rapid response is highly predictive of an eventual sustained
virologic response (SVR) at 24 weeks after the end of therapy.
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Fig. 1. Recognition of HCV RNA by RIG-I and TLR3 and activation of
type I interferon transcription. The event that is believed to trigger the
innate immune response toHCV infection is the recognition of one or more
pathogen-associated molecular patterns encoded in the HCVRNA. TLR3
recognizes double-stranded RNA (dsRNA) within endosomes and in turn
activates the protein kinaseTBK1 through the adaptor proteinTRIF.RIG-
I preferentially recognizes single-stranded RNA with a terminal 50-
triphosphate (ppp) over dsRNA. RIG-I activates the protein kinase IKKe
through the Cardif adaptor protein. Both TBK1 and IKKe phosphorylate
the transcription factor IRF-3, which leads to its homodimerization,
nuclear translocation, and stimulation of interferon-b gene transcription.
The HCV nonstructural protein NS3-4A speciﬁcally cleaves TRIF and
Cardif, thus blocking the innate immune recognition of HCV infection.
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where they activate interferon-b gene transcription.
Secreted interferon-b acts in both an autocrine and par-
acrine manner to stimulate the interferon-a/b receptor
tyrosine kinase (IFNAR), which is a heterodimer of
IFNAR-1 and IFNAR-2. The activated receptor recruits
and phosphorylates the tyrosine kinases Jak1 and Tyk2,
which in turn phosphorylate STAT1 and STAT2. Phos-
phorylated STAT1 and STAT2 combine with IRF9 to
form the heterotrimeric transcription factor known as
ISGF3. ISGF3 binds to the interferon-stimulated
response element upstream of interferon-stimulated
genes (ISGs) to promote their transcription. One of these
ISGs is IRF-7, which ampliﬁes interferon-a and -b tran-
scription [1], thus generating a positive feedback loop for
the ampliﬁcation of type I interferon signaling.
The pathway of endogenous type I interferon signal-
ing outlined above is the same as that used by exoge-
nously administered interferon-a for the treatment of
HCV infection. Namely, pharmacologic doses of inter-
feron-a activate the Jak-STAT signal transduction path-
way through IFNAR binding and ultimately stimulate
ISG transcription.
Microarray studies have identiﬁed over 200 ISGs
with diverse functions. Many of these, such as the
dsRNA dependent protein kinase (PKR), 20-50-oligoade-nylate synthetase (OAS), and myxovirus resistance 1
(M  1) are known to have direct antiviral functions.
1.2. Interferon and the adaptive immune response to HCV
In addition to its crucial role in regulating innate anti-
viral immunity, type I interferon also enhances the
adaptive immune response to HCV. For example,
immunoproteasome subunits are induced by type I
interferon, which stimulates antigen processing and thus
may enhance the adaptive immune response to HCV
infection [2]. Furthermore, type I interferon stimulates
the proliferation of memory T cells [3], enhances den-
dritic cell diﬀerentiation [4,5], and upregulates class I
MHC expression on hepatocytes [6]. Type I interferons,
therefore, exert their antiviral eﬀects on HCV both
through direct antiviral mechanisms as well as indirect
immunomodulatory mechanisms.
1.3. Resistance of HCV to interferon
Although we have made great strides in the therapy
of chronic HCV infection, the combination of pegylated
interferon and ribavirin is able to produce a sustained
virologic response (SVR) in only about 55% of all
patients [7,8]. The response of the HCV viral load to
therapy is often divided into three categories (Fig. 2).
A null response is conventionally deﬁned as a decline
in HCV viral load by less than 2 log10 at 12 weeks, while
a partial or slow response denotes a decline in HCV
RNA by over 2 log10 but with detectable viremia at
week 12 and clearance only by week 24. Slow responders
have a lower chance of attaining a SVR compared to
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serum HCV RNA at 12 weeks, or rapid responders,
who have lost detectable RNA by 4 weeks of treatment.
Current interferon-based therapy fails to work in so
many patients likely because of a combination of viral
and host factors. Virally encoded proteins directly inhibit
innate immunity and may also inhibit adaptive immunity
(Table 1). It is also known that there are ﬁxed host fac-
tors that are associated with treatment responsiveness,
such as race and age [9]. Additional modiﬁable host fac-
tors such as obesity, insulin resistance, and hepatic stea-
tosis may adversely aﬀect the outcome of treatment.
Interestingly, it should be pointed out that patients
with acute HCV infection experience far higher rates
of SVR (80–90%) when treated within 12 weeks of diag-
nosis by standard interferon-based regimens than those
with chronic infection [10,11], indicating that the viral
and host mechanisms that contribute to interferon non-
response take time to become established during the
acute or early stages of HCV infection.
1.4. Molecular mechanisms of viral interference with
innate immunity
As described above, the HCV PAMP sensors RIG-I
and TLR3 signal through the adaptor proteins CardifTable 1
Suppression of innate and adaptive immune responses by HCV structural
and nonstructural proteins.
Innate immunity Adaptive immunity
Core
 SOCS3 induction? inhibition
of STAT1 phosphorylation [15]
 Direct binding to STAT1?
proteasomal degradation and
inhibition of STAT1
phosphorylation [16,17]
 PP2A upregulation? STAT1
and binding by PIAS1 [18]
 Inhibition of T-cell
proliferation
by binding
to gC1q receptor [24]
E2
 Binding and inhibition
of PKR [20]
NS3-4A
 Cleavage of the adaptor
proteins
Cardif and TRIF [12–14]
NS5A
 Binding and inhibition
of PKR [19]
NS5B
 Error-prone RNA
polymerase? high
viral mutation
rates and escape from
adaptive
immune responses [27]and TRIF, respectively (Fig. 1). Remarkably, the HCV
NS3-4A serine protease speciﬁcally cleaves both Cardif
[12,13] and TRIF [14] to inactivate signals initiated by
RIG-I and TLR3.
Speciﬁc NS3-4A protease inhibitors, therefore, not
only directly inhibit the HCV lifecycle by inhibiting
cleavage of the HCV polypeptide, but may also rescue
the NS3-4A mediated block of RIG-I and TLR3 signal-
ing and hence restore the innate immune pathway in
infected hepatocytes.
In addition to the eﬀect of NS3-4A on blocking
events upstream of interferon-b transcription, there is
evidence that other HCV proteins block interferon sig-
naling downstream of the interferon-a/b receptor itself.
Over-expression of HCV core protein leads to induction
of SOCS (Suppressors of Cytokine Signaling) 3 protein
[15], which in turn inhibits STAT1 phosphorylation by
Jak1. We have shown that HCV core also appears to
directly inhibit STAT1 by directly binding the STAT1
SH2 domain, leading to STAT1 proteasome-dependent
degradation as well as inhibition of STAT1 phosphory-
lation [16,17]. Core protein has been shown to act at yet
another level to inhibit type I interferon signaling
through the upregulation of protein phosphatase 2A
(PP2A). PP2A, in turn, inhibits protein arginine methyl-
transferase 1 (PRMT1), leading to hypomethylation of
STAT1. Hypomethylated STAT1 binds to the inhibitory
Protein Inhibitor of Activated STAT (PIAS1), which
prevents STAT1 from activating ISG transcription
[18]. Collectively, these mechanisms all lead to the atten-
uation of ISG expression by HCV in response to endog-
enous or exogenous interferon.
Finally, the antiviral eﬀects of several ISGs are also
blunted by HCV via diverse mechanisms. NS5A and
the envelope protein E2 directly interact with and
repress PKR, an antiviral ISG [19,20]. Another antiviral
ISG, 20-50-oligoadenylate synthetase, activates RNAse L
to cleave double-stranded RNA within predicted stem-
loop structures. One study found that genotype 2a
HCV RNA had more predicted RNAse L cleavage sites
than genotype 1a or 1b sequences and was more readily
cleaved in cell extracts [21]. Moreover, HCV RNA iso-
lated from patients on interferon therapy had acquired
mutations resulting in the loss of predicted RNAse L
cleavage sites. However, it has not been shown that
the loss of such cleavage sites is associated with inter-
feron non-response, and therefore the functional signif-
icance of these observations remains uncertain.
1.5. Viral interference with adaptive immunity
In addition to the well described evasion of innate
immunity by HCV, there is some evidence that HCV cir-
cumvents the adaptive immune response. Dendritic cells
recovered from the peripheral blood of individuals with
chronic HCV have impaired allostimulatory capacity
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to dendritic cells from healthy donors or those who had
cleared HCV infection [23]. HCV core protein has been
shown to inhibit T-cell proliferative responses in vitro
through a direct interaction with the gC1q receptor
[24], while CD8+ T-cell diﬀerentiation and function also
appear to be impaired in HCV infection [25,26].
The highly error-prone HCV RNA polymerase gives
rise to a large number of HCV quasispecies within the
infected individual. Viral escape from CD8+ T-cell
responses occurs by mutations within T-cell epitopes
[27] and is likely to be yet another mechanism by which
HCV is able to evade the adaptive immune response.
1.6. Fixed host factors and interferon non-response in
HCV infection
It is clear that host factors are also important contrib-
utors to HCV treatment responsiveness. Broadly speak-
ing, we can divide host factors into ﬁxed and modiﬁable
factors. The strongest known ﬁxed host factor for HCV
treatment response is race. Three studies comparing the
eﬀect of peginterferon and ribavirin in African-Ameri-
cans (AA) versus Caucasian-Americans (CA) have con-
sistently demonstrated that AA with genotype 1 HCV
infection achieve an SVR at rates signiﬁcantly lower
(19–28%) than CA (39–52%) by nearly a factor of two,
even after correcting for medication adherence and
peginterferon pharmacokinetics [28–31].
An important clue to the mechanism(s) that underlie
the inferiority of interferon response in AA can be
gleaned from the viral kinetics in treated patients. In
the Virahep-C study [30], signiﬁcantly fewer AA had
an undetectable HCV viral load (<50 IU/mL) compared
to CA at week 4 after start of therapy (10% versus 22%),
and this diﬀerence was seen at all of the subsequent time
points, such that the overall SVR was only 28% in AA
versus 52% in CA. However, when analyzed by rapid
virologic responder (RVR) status (i.e. undetectable
HCV RNA at week 4), those who had attained an
RVR were equally likely to achieve an SVR regardless
of race. Much of the diﬀerence in SVR between AA
and CA could be explained by the diﬀerence in fre-
quency of achievement of rapid and early virologic
response in the two groups, suggesting that the increased
rate of treatment failure among AA might be a result of
intrinsic defects in innate or adaptive immunity. An
important corollary of these ﬁndings is that on-treat-
ment responses (i.e. RVR) appear to supersede baseline
factors of responsiveness.
One major eﬀector of the innate immune response is
the transcription of interferon-stimulated genes.
Another study from the Virahep-C cohort using periph-
eral blood mononuclear cells (PBMC) found that the
number of genes whose expression levels changed by
at least 1.5-fold with a p-value of <0.001 during pegin-terferon/ribavirin treatment was signiﬁcantly higher in
marked responders (>3.5 log10 decrease at 4 weeks of
treatment) compared to poor responders (<1.4 log10
decrease) [32], suggesting that poor responders had a
blunted response to interferon at the gene transcription
level. Among the upregulated gene transcripts were
many well-known antiviral ISGs such as OAS1 and
M1. Surprisingly, AA patients had a higher number
of genes whose expression was signiﬁcantly altered
(upregulated or downregulated) by treatment compared
to CA among marked responders as well as among poor
responders.
In addition to blunted innate immune responses to
interferon in AA, adaptive immunity also appears to
be impaired in AA. HCV-speciﬁc CD4+ T cell responses
were measured by interferon-gamma secretion and were
found to be impaired in AA compared to CA in the
Virahep-C cohort, while CMV-speciﬁc responses were
similar between the two groups. Furthermore, stronger
pretreatment HCV-speciﬁc CD4+ responses were inde-
pendently associated with SVR [33].
The possible viral contribution to non-response has
been examined by direct sequencing of the full pretreat-
ment HCV genome from rapid responders versus non-
responders in the Virahep-C cohort [34]; this study
failed to identify signiﬁcant viral sequence clustering
among isolates when analyzed by viral response or race,
indicating that non-responders and AA are not infected
by distinct strains of HCV when compared to respond-
ers and CA, respectively. However, there appeared to
be more sequence diversity (compared to reference
HCV sequences) in certain viral genes in rapid respond-
ers than in null responders, and in genotype 1b (but not
1a) CA versus AA, even after taking known T-cell epi-
topes into account.
We have discussed the ﬁndings by Taylor et al. in
peripheral blood mononuclear cells that poor respond-
ers had blunted interferon-stimulated gene expression
compared to marked responders; do these ﬁndings hold
true in the liver, where HCV resides? Several studies
have examined the relationship between HCV treatment
non-response and gene expression in the liver [35–37]. In
the study by Chen et al., expression proﬁling of pretreat-
ment liver biopsies from patients with chronic HCV
infection identiﬁed 18 genes whose expression diﬀered
signiﬁcantly between responders (undetectable HCV
RNA at the ﬁrst post-treatment assessment) and non-
responders (detectable HCV RNA at end of treatment).
Among these were many ISGs, as expected. What was
unexpected was the ﬁnding that many of these ISGs
were actually upregulated in pretreatment biopsies from
non-responders compared to responders. Subsequent
studies by Feld et al. and Sarasin-Filipowicz et al. have
conﬁrmed the general ﬁnding that treatment non-
response is associated with broad baseline ISG tran-
scriptional upregulation.
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sion proﬁles in paired liver biopsies from 16 patients
obtained before and 4 h after a single dose of peginter-
feron. A key ﬁnding was that the great majority
(93%) of ISGs were expressed at the same absolute lev-
els in post-treatment biopsies in 4-week responders ver-
sus non-responders. However, non-responders displayed
minimal ISG induction over baseline because baseline
ISG expression was already broadly elevated. Another
important point was that preactivation of ISGs was
not observed in PBMCs from the same patients, indicat-
ing that baseline ISG preactivation in non-responders is
speciﬁc to the liver. It appears, therefore, that it is the
fold change of ISG induction over baseline in response
to interferon that is associated with treatment response,
rather than the absolute magnitude of ISG expression in
response to interferon.
A similar observation has been made in HCV-
infected chimpanzees, namely, that several ISGs were
basally upregulated in the livers of HCV-infected chim-
panzees compared to uninfected controls [38]. Further-
more, in contrast to the basal upregulation of ISGs in
HCV-infected chimpanzee liver, their transcriptional
induction by exogenous interferon was impaired com-
pared to uninfected controls.
We are therefore left with the observations that ISG
expression is elevated in HCV treatment non-responders
at baseline and that HCV infection may blunt the fur-
ther induction of ISGs by exogenous interferon; how-
ever, elevated basal ISG expression in non-responders
is clearly ineﬀective from the standpoint of viral clear-
ance. One potential explanation for why this might be
comes from expression proﬁling of liver biopsies from
humans at 24 h following a single dose of peginterfer-
on-alfa compared to control pretreatment biopsies from
a diﬀerent set of individuals [38]. The investigators
examined expression of SOCS3, which was discussed
earlier in this review and is thought to inhibit type I
interferon signaling by blocking STAT1 phosphoryla-
tion. Expression of SOCS3 decreased in both rapid
responders and non-responders after a single dose of
peginterferon; however, this decrease was signiﬁcantly
greater in responders (deﬁned as >2 log10 decline in
HCV RNA at week 4 of treatment) than in slow
responders (<2 log10 decline).
How can we reconcile the data from these expression
proﬁling studies? First, it appears that ISG transcript
levels are basally elevated in non-responder liver tissue
compared to responders, though the elevated antiviral
ISGs are clearly inadequate on their own to clear
HCV infection. Second, further elevation in hepatic
ISG transcript levels in response to exogenous interferon
is blocked in non-responders. It is conceivable that the
observed blunting of hepatic ISG induction by exoge-
nous interferon in non-responders is mediated in part
by inhibitory proteins such as SOCS3. However, the ele-vated basal ISG expression in non-responders suggests
that there are additional blocks at the level of ISG
action; these blocks may be viral or host-mediated.
An important question is whether host genetic poly-
morphisms are associated with interferon treatment
response in chronic HCV infection. A candidate gene
analysis was used to study 118 single nucleotide poly-
morphisms (SNPs) from ISGs and interferon signaling
pathway genes in individuals from the Virahep-C cohort
for associations with SVR [39]. Three SNPs from the
OASL (OAS-like) gene were found to be weakly associ-
ated with SVR, though this study was limited by a small
sample size (n = 374). We anticipate that adequately
powered whole genome association studies will be neces-
sary to identify host genetic markers that modify inter-
feron sensitivity and HCV persistence.2. Modiﬁable host factors and interferon non-response in
HCV infection
In addition to ﬁxed host factors such as race, modiﬁ-
able risk factors contribute to interferon non-response.
Multivariate analysis of the Virahep-C cohort found
that the HOMA index, a measure of insulin resistance,
was independently associated with SVR [40]. Although
insulin resistance was more prevalent among AA com-
pared to CA, this alone did not account for the diﬀer-
ences in SVR between the two groups. The HOMA
index had also been found to correlate with treatment
response in a previous study of genotype 1-infected
patients treated with peginterferon and ribavirin [41].
In that study, patients with a normal HOMA (<2) had
an SVR of 60.5%, compared to an SVR of 40% in
patients with moderate insulin resistance (HOMA 2–4)
and only 20% in patients with severe insulin resistance
(HOMA >4).
One mechanism by which insulin resistance and obes-
ity may contribute to interferon non-response is through
upregulation of SOCS3 [42]. SOCS3 blocks interferon
signaling and also may exacerbate insulin resistance by
promoting ubiquitin-mediated degradation of insulin
receptor substrate (IRS) 1 and 2 [43]. However, it
remains an open question as to whether reversal of insu-
lin resistance results in higher rates of HCV treatment
response in vivo. Clinical trials are underway to deter-
mine whether adding pharmacologic insulin sensitizers,
such as thiazolidinediones, to standard HCV therapy
will increase SVR.
Finally, there have been studies that claim to show
the presence of interferon-neutralizing antibodies in
the serum of patients with chronic HCV infection trea-
ted with interferon. One study found neutralizing anti-
bodies to interferon in 39% of patients experiencing
virologic breakthrough on interferon monotherapy
[44]. Such a high incidence of neutralizing antibodies
A.W. Tai, R.T. Chung / Journal of Hepatology 50 (2009) 412–420 417on interferon therapy has not been reported in other
studies. Another study identiﬁed neutralizing antibodies
to interferon in 14% of patients treated with interferon
monotherapy; there was no signiﬁcant association, how-
ever, between the presence of neutralizing antibodies
and treatment response [45].
2.1. Overcoming barriers to interferon non-response in
HCV infection
The signiﬁcant progress made thus far in understand-
ing the viral and host factors that contribute to treat-
ment non-response indicate several routes by which
these barriers may be overcome (Table 2). With regard
to viral factors, the NS3-4A protease is an excellent ther-
apeutic target due to its essential role in the HCV life
cycle as well as its role in inactivation of intracellular
innate immune responses. Indeed, NS3-4A protease
inhibitors reverse Cardif and TRIF cleavage in liver
biopsy samples from HCV-infected patients (D. Morad-
pour, personal communication). The high eﬃcacy of
NS3-4A protease inhibitors in clinical trials could poten-
tially be explained by their ability to restore innate
immune signaling in addition to their known direct anti-
viral eﬀects. It should be noted that a number of potent
NS5B polymerase inhibitors have demonstrated antivi-
ral eﬃcacies in vitro and in vivo on par with NS3-4A
inhibitors. These ﬁndings raise the possibility that any
potent direct antiviral agent could liberate innate immu-
nity through its reduction of viral protein levels. A
recent report comparing two NS3-4A protease inhibi-
tors with a nonnucleoside polymerase inhibitor found
that the polymerase inhibitor was unable to rescue inter-
feron-beta promoter activation in response to challenge
with Sendai virus in cell culture systems of HCV infec-
tion [46]. The protease inhibitors did rescue interferon-
beta promoter activation but only at concentrations
100-fold higher than the antiviral EC50. However, itTable 2
Possible approaches to overcoming interferon resistance.
Approach Proposed mechanism(s)
NS3-4A protease inhibitors Inhibition of Cardif and TRIF cleavage
by NS3-4A and restoration
of interferon b activation [12–14]
S-Adenosyl-L-methionine
and betaine
Restoration of STAT1 methylation
and rescue from PIAS1 inhibition [47]
High-dose ribavirin Interferon sensitization by increasing
ISG expression and decreasing
expression of inhibitors of interferon
signaling [36]
Reversal of insulin
resistance
Decreasing SOCS3 expression [42]
Targeting host cofactors
of HCV lifecycleshould be pointed out that NS3-4A protein expression
was only partially abolished by the agents tested in this
study due to the relatively short treatment duration
(52 h), and it remains possible that interferon respon-
siveness can be restored by longer duration of direct
antiviral therapy that more eﬀectively suppresses viral
protein expression. Regardless, the best test of whether
direct antiviral inhibitors can restore interferon respon-
siveness is being carried out in clinical trials of NS3-4A
protease inhibitors in prior peginterferon/ribavirin non-
responders; early data from such trials suggest that on-
treatment responses and SVR can be achieved in a large
portion of prior non-responders.
Another potential means of overcoming interferon
non-response might be to give higher doses of exogenous
interferon or to use interferon variants with more favor-
able pharmacokinetics or pharmacodynamics. It
appears, however, that high-dose interferon or interferon
variants such as albumin-interferon or consensus inter-
feron do not confer clinically signiﬁcant beneﬁts over
standard therapy in non-responders. Furthermore, many
of these regimens are associated with signiﬁcant toxici-
ties. Our experience to date, therefore, suggests that the
downstream blocks to interferon response imposed by
viral and host factors cannot be circumvented simply
by overwhelming them with higher doses of interferon.
How might we rescue these downstream defects? One
approach might be to activate ISGs through interferon-
independent mechanisms; further work would be neces-
sary to identify the key eﬀector antiviral ISGs among the
many that have been identiﬁed to date. A second would
be to reverse the eﬀects of HCV on Jak-STAT signaling
pathway members, such as hypomethylation of STAT1
described earlier in this review. S-Adenosyl-L-methio-
nine and betaine can restore STAT1 methylation [47]
and therefore might act as interferon enhancers. Yet
another approach is to block inhibitors of interferon sig-
naling such as SOCS3.3. The anti-HCV actions of ribavirin
The antiviral mechanism of ribavirin remains some-
what controversial. The current prevailing hypothesis
is that ribavirin acts as a mutagen to increase the likeli-
hood of lethal mutations (‘‘error catastrophe”) in the
HCV genome, while other evidence supports a possible
immune modulatory activity. These two mechanisms
are not mutually exclusive. One study found an increase
in HCV mutation frequency in HCV replicon cell lines
treated with ribavirin, as well as in patients treated with
ribavirin monotherapy but not in those receiving combi-
nation peginterferon and ribavirin, in whom the muta-
tion frequency actually fell on treatment [48]. Another
study also identiﬁed an increase in HCV mutation
frequency in humans treated with ribavirin monotherapy
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a third study in patients receiving ribavirin monotherapy
followed by combination interferon/ribavirin treatment
did not reveal any detectable increase in HCV mutations
[50]. Evidence that ribavirin may modulate the innate
immune response comes from a tissue expression proﬁl-
ing study of liver biopsies from patients treated with a
single dose of peginterferon with or without ribavirin,
compared to those from matched untreated controls.
It was shown that the addition of ribavirin increased
expression levels of several ISGs and also decreased sev-
eral negative regulators of interferon signaling such as
PP2A and SOCS1 [36]. Ribavirin may therefore be act-
ing as an interferon ‘‘sensitizer”.
In contrast to the relative ineﬀectiveness of increasing
interferon dose for HCV treatment, there is evidence that
higher doses of ribavirin may be superior to the current
recommended ribavirin dosing regimens. A recent ran-
domized study compared ‘‘higher-dose” weight-based
ribavirin (15.2 mg/kg/d) plus epoetin alfa to ‘‘standard”
weight-based dosing (13.3 mg/kg/d) with or without
epoetin alfa in genotype 1, treatment-naı¨ve patients
[51]. The authors found that the high-dose group had a
signiﬁcantly better SVR than the standard groups (49%
versus 34% and 22%) due to a signiﬁcantly lower relapse
rate in the high-dose group (8% versus 38%).4. Another avenue: targeting host cofactors
A very promising strategy to overcome viral resis-
tance to current therapy is to identify and target host
proteins that support the HCV life cycle. For example,
the human protein cyclophilin B interacts with the geno-
type 1 NS5B HCV RNA polymerase to stimulate bind-
ing to RNA [52]. The cyclophilin B inhibitor Debio-025
potently suppresses genotype 1 HCV replication in vivo
[53]. Another example of a ‘‘drugable” host cofactor is
FBL2, which requires lipid modiﬁcation by geranylger-
anylation for its function [54]. HMG-CoA reductase
inhibitors disrupt geranylgeranyl pyrophosphate synthe-
sis and inhibit HCV replication in cell culture models
[55]. Thus, host lipid biosynthesis inhibitors may be
another method of blocking HCV replication. On the
one hand, targeting host cofactors of the HCV life cycle
is attractive because it imposes a higher genetic barrier
for resistance than direct antiviral compounds. How-
ever, the principal drawback of this strategy is the
greater potential for cellular toxicity.5. Conclusion
In summary, HCV has evolved elaborate and broad
mechanisms to disarm both host innate and adaptive
immunity. These mechanisms favor viral persistenceeven in the face of exogenous interferon-based therapies.
Understanding the molecular mechanisms by which
HCV counteracts the host immune response will yield
novel therapeutic strategies. In addition, host factors
such as race and insulin resistance have substantial
impact on treatment responsiveness. We anticipate that
additional host factors such as genetic polymorphisms in
interferon-signaling genes and ISGs will be identiﬁed as
modulators of HCV treatment response. Modiﬁcation
of adverse host factors, where possible, may be another
opportunity to optimize HCV therapy.Acknowledgements
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